- Home
- LPRO vs BDTX Comparison
LPRO vs BDTX Comparison
Compare LPRO & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LPRO | BDTX |
|---|---|---|
| Founded | 2000 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.9M | 220.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | LPRO | BDTX |
|---|---|---|
| Price | $1.69 | $2.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | $2.83 | ★ $10.60 |
| AVG Volume (30 Days) | 541.8K | ★ 1.7M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.38 |
| Revenue | $16,948,000.00 | ★ $70,000,000.00 |
| Revenue This Year | $306.66 | N/A |
| Revenue Next Year | $7.97 | N/A |
| P/E Ratio | ★ N/A | $7.38 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.70 | $1.20 |
| 52 Week High | $6.75 | $4.94 |
Technical Indicators
Market Signals| Indicator | LPRO | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.69 | 30.62 |
| Support Level | $1.77 | $2.61 |
| Resistance Level | $1.81 | $2.84 |
| Average True Range (ATR) | 0.09 | 0.26 |
| MACD | -0.00 | -0.07 |
| Stochastic Oscillator | 15.63 | 26.81 |
Price Performance
Historical ComparisonAbout LPRO Open Lending Corporation
Open Lending Corp is engaged in providing automated lending services to financial institutions. The company offers loan analytics, risk-based pricing, risk modeling, and automated decision technology. Its Lenders Protection Program ("LPP") enables automotive lenders to make loans that are largely insured against, losses from defaults.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.